• Type: Antibiotic
  • Dosage Forms: CAP 50mg
  • Routes of Administration: Oral
  • Common Trade Names: Lamprene

Adult Dosing

Hansen's disease, multibacillary

  • 50mg PO qd x 12mo in combination with rifampin and dapsone
    • Give 300mg PO qmo x 12mo in addition to daily dose

Erythema nodosum leprosum

  • 100mg PO bid x12wk, then 100mg PO qd 12-24wk
    • Start 100mg PO tid x12wek

Pediatric Dosing

Hansen's disease, multibacillary

  • 10-14 yo: 50mg PO qod AND 150mg PO qmo x12mo in combination with rifampin and dapsone
  • >15 yo: 50mg PO qd AND 300mg PO qmo x 12mo in combination with rifampin and dapsone

Special Populations

  • Pregnancy Rating: C
  • Lactation risk: Caution advised
  • Renal dosing: not defined
  • Hepatic dosing: not defined


  • Allergy to class/drug
  • Caution:

Adverse Reactions




  • Half-life: 70 days
  • Metabolism: Unknown
  • Excretion: Feces primarily

Mechanism of Action

  • Bacteriostatic or bactericidal: Binds to mycobacterial DNA, inhibiting growth


See Also


  • Lexicomp
  • Aronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  • FDA Safety Alert. Med Watch. Lamprene (Clofazimine). Food and Drug Administration website. Available at Accessed November 11, 2016.
  • Freerksen E, Seydel JK. Critical comments on the treatment of leprosy and other mycobacterial infections with clofazimine. Arzneimittelforschung. 1992;42(10):1243-5. Review. [PubMed 1472145]
  • Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: Recommended Treatment Regimens. http://www.hansensdisease/diagnosis/recommendedtreatment.html. Accessed on March 31, 2016.
  • Holdiness MR. Clinical pharmacokinetics of clofazimine. A review. Clin Pharmacokinet. 1989;16(2):74-85. [PubMed 2656045]
  • Lamprene (clofazimine) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals; January 2019.
  • Legendre DP, Muzny CA, Swiatlo E. Hansen's disease (Leprosy): current and future pharmacotherapy and treatment of disease-related immunologic reactions. Pharmacotherapy. 2012;32(1):27-37. [PubMed 22392826]
  • Szeto W, Garcia-Buitrago MT, Abbo L, Rosenblatt JD, Moshiree B, Morris MI. Clofazimine enteropathy: a rare and underrecognized complication of mycobacterial therapy. Open Forum Infect Dis. 2016;3(3):ofw004. [PubMed 27800519]
  • World Health Organization. Drugs Used in Leprosy. Accessed April 6, 2016.
  • World Health Organization. WHO Expert Committee on Leprosy. World Health Organ Tech Rep Ser. 2012;(968):1-61, 1 p following 61. [PubMed 22970604]